Do persistent injury and EPA-derived mediators affect inflammatory signaling differently?

Persistent injury and neuropathic pain can participate in a self-reinforcing neuroimmune state, while EPA-derived specialized pro-resolving mediators (SPMs) have a distinct, experimentally supported role in actively resolving inflammation. The two propositions differ importantly in evidentiary maturity: injury-related signaling is biologically plausible in humans, whereas resolvin biology is established mainly in preclinical systems.

Neuroimmune signaling in persistent pain

• Persistent nerve or tissue injury produces ongoing peripheral input that can activate microglia and astrocytes. In experimental models, glial signaling through purinergic and Toll-like-receptor pathways, MAPK/NF-κB activation, and mediators including IL-1β, TNF-α, IL-6, chemokines, and BDNF can increase neuronal excitability and central sensitization.
• A reciprocal pain–inflammation loop is plausible, but human evidence in postherpetic neuralgia and chronic postsurgical pain is heterogeneous and chiefly correlational. Reported findings include associations of serum IL-6 with PHN severity, elevated CSF IL-8 in some intractable PHN cases, and CCL2/BDNF changes in a small chronic inguinal-pain cohort; none establish that pain itself causally maintains inflammation.

Resolution mechanisms of EPA-derived SPMs

• Resolvin E1 (RvE1) and resolvin E2 (RvE2) do more than broadly suppress inflammatory signals. They limit neutrophil migration and infiltration—RvE1 through ChemR23-related signaling and antagonism of leukotriene B4 signaling at BLT1—while enhancing macrophage efferocytosis, phagocytosis, and debris clearance. RvE2 may also increase IL-10.
• This coordinated reduction in further leukocyte influx plus active clearance and macrophage functional reprogramming is characteristic of inflammation resolution. In nerve-injury animal models, RvE1 also reduces neuropathic hypersensitivity, with reduced spinal microglial activation reported.

Clinical implications

• No human trials establish RvE1/RvE2 dosing, pharmacokinetics, safety, resolution endpoints, or efficacy for neuropathic pain. Effects and safety of omega-3 supplements, including high-dose EPA-associated modest bleeding and atrial-fibrillation risk, cannot be assumed to apply to direct resolvin therapy.

Bottom line

• Persistent injury-related inflammatory signaling and EPA-SPM-driven active resolution are well-supported mechanistic concepts, but their use as clinical explanations or treatments for human neuropathic pain remains unproven.